Shukin I A, Lebedeva A V, Soldatov M A, Fidler M C
Pirogov Russian National Research Medical University, Moscow, Russia.
Pirogov City Clinical Hospital #1, Moscow, Russia.
Zh Nevrol Psikhiatr Im S S Korsakova. 2018;118(7):25-29. doi: 10.17116/jnevro20181187125.
To evaluate the efficacy of cytoflavin in the treatment of patients with chronic cerebral ischemia and mild cognitive impairment predominantly of vascular origin.
Treatment results of 140 patients, aged 60-74, with chronic cerebral ischemia were analyzed. The main group included 77 patients (35 men and 42 women of average age 66.38±4.64 years) who received cytoflavin throughout the observation period: 2 tablets twice a day 30 minutes before meals. The comparison group included 63 patients (26 men and 37 women of average age 67.48±5.22 years) who during the whole period of observation received ethyl methyl hydroxypyridine succinate: 2 tablets (250 mg) twice a day, according to the same scheme as in the main group. Treatment efficacy was assessed by neuropsychological testing and P300 evoked potentials.
During treatment, there was an improvement in neurophysiological parameters in both groups, which was more pronounced in patients treated with cytoflavin: their P300 amplitude increased by1.3 times in the left hemisphere (from 9.21 (8.36, 10.11) to 12.41 (10.23, 13.37 μV) and 1,7 times in the right hemisphere (from 6.48 (5.26, 7.35) to 11.04 (9.29, 12.18) μV). Our study confirms the advisability of using drugs that have complex cytoprotective and energy-correcting mechanism in patients with cognitive impairment. Cytoflavin has shown the high efficacy and safety and can be recommended as part of complex therapy for cognitive disorders. Using simple and inexpensive instrumental methods (assessment of cognitive P300 evoked potential) along with diagnostic scales in patients with cognitive impairment can significantly objectify the assessment of treatment dynamics.
评估细胞色素C在治疗主要由血管源性引起的慢性脑缺血和轻度认知障碍患者中的疗效。
分析了140例年龄在60 - 74岁的慢性脑缺血患者的治疗结果。主要组包括77例患者（35名男性和42名女性，平均年龄66.38±4.64岁），在整个观察期内服用细胞色素C：每天两次，每次2片，饭前30分钟服用。对照组包括63例患者（26名男性和37名女性，平均年龄67.48±5.22岁），在整个观察期内服用琥珀酸乙甲基羟基吡啶：每天两次，每次2片（250毫克），服用方案与主要组相同。通过神经心理学测试和P300诱发电位评估治疗效果。
治疗期间，两组患者的神经生理参数均有改善，在服用细胞色素C治疗的患者中更为明显：其左半球P300波幅增加了1.3倍（从9.21（8.36，10.11）增至12.41（10.23，13.37）μV），右半球增加了1.7倍（从6.48（5.26，7.35）增至11.04（9.29，12.18）μV）。我们的研究证实，对于认知障碍患者，使用具有复杂细胞保护和能量校正机制的药物是可取的。细胞色素C已显示出高效性和安全性，可推荐作为认知障碍综合治疗的一部分。在认知障碍患者中，使用简单且廉价的仪器方法（评估认知P300诱发电位）以及诊断量表可以显著客观地评估治疗动态。
